BioMed X Institute and Boehringer Ingelheim completed a study on schizophrenia's genetic pathways, identifying differentially expressed genes in patients' brains for potential new therapies.
BioMed X Institute and Boehringer Ingelheim completed a study on schizophrenia's genetic pathways using cell and mouse models, post-mortem human brain samples, and oligodendrocytes. The research revealed differentially expressed genes in schizophrenia patients' brains, which could help design new therapies for schizophrenia and disorders like major depressive disorder or bipolar disorder. The partnership aims to address mental health research's unmet needs.
May 28, 2024
5 Articles